Pulmonary fibrosis

6 trials 4 recruiting MedDRA PT
6 Registered trials
4 Recruiting
5 Unique sponsors
4 Unique IMPs
4 Commercial trials
Drug classes (ATC)
— ATC code not specified 5
B Haematology (ATC B) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 4 substances
Phase III: 2 Phase II: 1 Phase I/II: 2 Phase I: 1

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase III

2 trials
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    ADMILPARANT
    2023-503699-25-00 15 countries 2024 n=249
    Recruiting
  • United Therapeutics Corp. Commercial
    TREPROSTINIL
    2023-504904-26-00 5 countries 2025 n=242
    Recruiting

Phase II

1 trial
  • Avalyn Pharma Inc. Commercial
    PIRFENIDONE
    2023-508429-29-00 7 countries 2024 n=182
    Recruiting

Phase I/II

2 trials
  • St Antonius Hospital Academic
    [AL[18F]F]FAPI-74
    2023-503686-26-00 1 country n=20
    Not authorised
  • St Antonius Hospital Academic
    [AL[18F]F]FAPI-74
    2023-503686-26-02 1 country 2025 n=20
    Recruiting

Phase I

1 trial
  • Gat Therapeutics S.L. Commercial
    IMP not specified
    2023-504426-19-00 1 country 2024 n=52
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
St Antonius Hospital Academic 2 Phase I/II 1
Gat Therapeutics S.L. Commercial 1 Phase I 0
Avalyn Pharma Inc. Commercial 1 Phase II 1
Bristol-Myers Squibb Services Unlimited Company Commercial 1 Phase III 1
United Therapeutics Corp. Commercial 1 Phase III 1
New trials by year
2024
3
2025
2
← All indication landscapes